Cell Therapy

August 31, 2017
The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies
Categories

The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

[vc_row][vc_column][vc_column_text] Gilead Sciences has ended its M&A moratorium with an $11.9B all-cash acquisition of CAR-T Cell Therapy pioneers Kite Pharma. Kite’s leading drug Axi-Cel is expected […]
Do you like it?
Read more
April 12, 2017
GE Healthcare Adds to Its Cell Therapy Portfolio with Acquisition of Asymptote
Categories

GE Healthcare Adds to Its Cell Therapy Portfolio with Acquisition of Asymptote

[vc_row][vc_column][vc_column_text]GE Healthcare recently announced the acquisition of British cryogenic processing company Asymptote for an undisclosed price, strengthening its cell therapy portfolio with technologies designed to enable […]
Do you like it?
Read more
January 12, 2017
Categories

Drug Development IPO Analysis: Over $4.2B Raised Globally in Q4 2016 Despite Continued NASDAQ Decline

[vc_row][vc_column][vc_column_text] Whilst the depression in the value and frequency of Drug Development IPOs on the NASDAQ market continued throughout the fourth quarter of 2016, a combined […]
Do you like it?
Read more
Prev page
123
Next page